Induction Therapy With TCD Regimen (Thalidomide, Cyclophosphamide, Dexamethasone) Followed by Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients
Phase II clinical trial for the patients with newly diagnosed. TCD (thalidomide,
cyclophosphamide and dexamethasone) will be applied for the patients as an induction
chemotherapy, followed by high dose chemotherpy and autologous stem cell transplantation.
Afterthen, they will receive TD (thalidomide and dexamethasone) maintenance therapy for one
year.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate of TCD induction Therapy
Je-Jung Lee, MD, PhD
Principal Investigator
Chonnam National University Hospital
Singapore: Domain Specific Review Boards
KMM53
NCT00349115
June 2006
June 2008
Name | Location |
---|